PMID- 36849850
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 42
IP  - 8
DP  - 2023 Aug
TI  - Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial 
      spondyloarthritis: a bibliometric study.
PG  - 1999-2011
LID - 10.1007/s10067-023-06540-9 [doi]
AB  - Various biological disease-modifying anti-rheumatic drugs (bDMARDs) have been 
      applied for treating axial spondyloarthritis (axSpA). However, there is a glaring 
      absence of a bibliometric analysis on bDMARDs against axSpA. Articles related to 
      use of bDMARDs in treating axSpA published from 2004 to 2022 were searched from 
      the Web of Science Core Collection. VOS viewer 1.6.18 and CiteSpace 6.1.R2 were 
      used to analyze and visualize the quantity and citations of publications, as well 
      as to identify "research hotspots" and trends in this field. BibExcel version 
      1.0.0 and gCLUTO version 1.0 were used to build matrices for bi-clustering 
      analysis. A total of 2546 articles referring to bDMARDs for treatment of axSpA 
      were included in this bibliometric analysis. Overall, the number of publications 
      has been increasing steadily annually. The USA (23.21%, 591 publications) ranked 
      first with the largest output of papers, followed by Germany, and the 
      Netherlands. Rheumazentrum Ruhrgebiet ranked first as the most frequent publisher 
      (119 articles). Annals of the Rheumatic Diseases published the most documents 
      (6.76%, 172 publications) in this field. The predominant hotspots have been 
      "tuberculosis," "IL-17," and "quality of life" in the field until 2020. Since 
      2015, "biosimilar pharmaceuticals" has retained the popularity. Current research 
      hotspots are "spinal radiographic progression," Janus kinase (JAK) inhibitors, 
      and adverse events (AEs). Machine learning has become popular gradually. 
      Globally, there has been a steady increase in the number of studies on bDMARDs 
      use against axSpA. JAK inhibitors, spinal radiographic progression, biosimilar 
      pharmaceuticals, and AEs are current research hotspots. Machine learning is 
      emerging research hotspots and trends in this field.
CI  - (c) 2023. The Author(s), under exclusive licence to International League of 
      Associations for Rheumatology (ILAR).
FAU - He, Qian
AU  - He Q
AUID- ORCID: 0000-0002-3203-696X
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Chen, Jia-Qi
AU  - Chen JQ
AUID- ORCID: 0000-0002-1643-5450
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Yu, Xin-Bo
AU  - Yu XB
AUID- ORCID: 0000-0003-2366-5147
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Liao, Jia-He
AU  - Liao JH
AUID- ORCID: 0000-0001-7025-1022
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Huang, Zi-Wei
AU  - Huang ZW
AUID- ORCID: 0000-0002-6907-5866
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Yang, Jian-Ying
AU  - Yang JY
AUID- ORCID: 0000-0002-3009-8702
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Wu, Tzu-Hua
AU  - Wu TH
AUID- ORCID: 0000-0002-3385-7997
AD  - Beijing University of Chinese Medicine, Beijing, China.
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China.
FAU - Song, Wei-Jiang
AU  - Song WJ
AUID- ORCID: 0000-0002-2092-4775
AD  - Traditional Chinese Medicine Department, Peking University Third Hospital, 
      Beijing, China.
FAU - Luo, Jing
AU  - Luo J
AUID- ORCID: 0000-0002-2454-2168
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China. 
      luojinggg@sina.com.
AD  - Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China. luojinggg@sina.com.
FAU - Tao, Qing-Wen
AU  - Tao QW
AUID- ORCID: 0000-0002-9163-8426
AD  - Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship 
      Hospital, No. 2 Yinghua East Road, Chaoyang District, Beijing, 100029, China. 
      taoqg1@sina.com.
AD  - Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China. taoqg1@sina.com.
LA  - eng
GR  - ZRJY2021-QM14/China-Japan Friendship Hospital/
GR  - 2022-NHLHCRF-LX-02/National High Level Hospital Clinical Research Funding/
GR  - 2020-4-40610/Capital's Funds for Health Improvement and Research/
GR  - 2019-ZX-006/National Regional Traditional Chinese Medicine (Specialty) Treatment 
      Center Project/
GR  - 2011-ZDZK-001/National Key Clinical Specialty Building Project/
PT  - Journal Article
PT  - Review
DEP - 20230227
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Humans
MH  - *Biosimilar Pharmaceuticals/therapeutic use
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Axial Spondyloarthritis
MH  - Bibliometrics
MH  - *Janus Kinase Inhibitors
MH  - Pharmaceutical Preparations
OTO - NOTNLM
OT  - Axial spondyloarthritis
OT  - Bibliometric analysis
OT  - Biological disease-modifying anti-rheumatic drugs
OT  - Hotspot
OT  - Knowledge mapping
EDAT- 2023/03/01 06:00
MHDA- 2023/07/17 06:42
CRDT- 2023/02/28 00:30
PHST- 2022/11/07 00:00 [received]
PHST- 2023/02/04 00:00 [accepted]
PHST- 2023/01/14 00:00 [revised]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/02/28 00:30 [entrez]
AID - 10.1007/s10067-023-06540-9 [pii]
AID - 10.1007/s10067-023-06540-9 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2023 Aug;42(8):1999-2011. doi: 10.1007/s10067-023-06540-9. Epub 
      2023 Feb 27.